These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22500138)

  • 1. Issues related to recent dengue vaccine development.
    Konishi E
    Trop Med Health; 2011 Dec; 39(4 Suppl):63-71. PubMed ID: 22500138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dengue vaccine].
    Konishi E
    Nihon Rinsho; 2011 Sep; 69(9):1617-21. PubMed ID: 21922763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a live attenuated dengue virus vaccine using reverse genetics.
    Blaney JE; Durbin AP; Murphy BR; Whitehead SS
    Viral Immunol; 2006; 19(1):10-32. PubMed ID: 16553547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges for the formulation of a universal vaccine against dengue.
    Chokephaibulkit K; Perng GC
    Exp Biol Med (Maywood); 2013 May; 238(5):566-78. PubMed ID: 23856907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement-independent dengue virus type 1 infection-enhancing antibody reduces complement-dependent and -independent neutralizing antibody activity.
    Yamanaka A; Konishi E
    Vaccine; 2016 Dec; 34(51):6449-6457. PubMed ID: 27866774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using recombinant DNA technology for the development of live-attenuated dengue vaccines.
    Lee HC; Butler M; Wu SC
    Enzyme Microb Technol; 2012 Jul; 51(2):67-72. PubMed ID: 22664189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dengue vaccines: challenges, development, current status and prospects.
    Ghosh A; Dar L
    Indian J Med Microbiol; 2015; 33(1):3-15. PubMed ID: 25559995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Animal Models in Studying Roles of Antibodies and Their Secretion Cells in Dengue Vaccine Development.
    Chokephaibulkit K; Chien YW; AbuBakar S; Pattanapanyasat K; Perng GC
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33167518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dengue hemorrhagic fever - A systemic literature review of current perspectives on pathogenesis, prevention and control.
    Wang WH; Urbina AN; Chang MR; Assavalapsakul W; Lu PL; Chen YH; Wang SF
    J Microbiol Immunol Infect; 2020 Dec; 53(6):963-978. PubMed ID: 32265181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sculpting humoral immunity through dengue vaccination to enhance protective immunity.
    Crill WD; Hughes HR; Trainor NB; Davis BS; Whitney MT; Chang GJ
    Front Immunol; 2012; 3():334. PubMed ID: 23162552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dengue virus vaccine development.
    Yauch LE; Shresta S
    Adv Virus Res; 2014; 88():315-72. PubMed ID: 24373316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population.
    Montecillo-Aguado MR; Montes-Gómez AE; García-Cordero J; Corzo-Gómez J; Vivanco-Cid H; Mellado-Sánchez G; Muñoz-Medina JE; Gutiérrez-Castañeda B; Santos-Argumedo L; González-Bonilla C; Cedillo-Barrón L
    J Immunol Res; 2019; 2019():7239347. PubMed ID: 31565661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive genomic recoding by codon-pair deoptimization selective for mammals is a flexible tool to generate attenuated vaccine candidates for dengue virus 2.
    Stauft CB; Song Y; Gorbatsevych O; Pantoja P; Rodriguez IV; Futcher B; Sariol CA; Wimmer E
    Virology; 2019 Nov; 537():237-245. PubMed ID: 31539771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.
    Shukla R; Ramasamy V; Shanmugam RK; Ahuja R; Khanna N
    Front Cell Infect Microbiol; 2020; 10():572681. PubMed ID: 33194810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dengue vaccine.
    Simasathien S; Watanaveeradej V
    J Med Assoc Thai; 2005 Nov; 88 Suppl 3():S363-77. PubMed ID: 16858980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dengue NS1-specific antibody responses: isotype distribution and serotyping in patients with Dengue fever and Dengue hemorrhagic fever.
    Shu PY; Chen LK; Chang SF; Yueh YY; Chow L; Chien LJ; Chin C; Lin TH; Huang JH
    J Med Virol; 2000 Oct; 62(2):224-32. PubMed ID: 11002252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.